A medical marijuana facility in Massachusetts. Photo: Barry Chin/The Boston Globe via Getty Images

Once-off-limits drugs are gaining a bigger foothold in the health care market as scientists reassess how they work and what they're capable of.

What to watch: Cannabis is the leader on this front — marijuana is a booming business, and the FDA approved a drug last year derived from cannabis — but psychedelics are also getting a closer look from pharmaceutical companies.

Details: CNBC reports that Walgreen's will sell cannabis-oil products, including creams, patches and sprays, in some 1,600 stores across 6 states. CVS embraced CBD drugs earlier this month.

For psychedelics, the FDA's approval of a "ketamine-like" drug to treat severe depression has already provided one popularity boost, CNBC's Christina Farr writes.

  • On the heels of that decision, ATAI, a German company specializing in "formerly stigmatized compounds," raised $40 million, for a valuation of $240 million.
  • "Biotech investors believe that psychedelic medicine will experience a revival in the wake of recent research studies as well as some early signals of support from regulators," Farr reports.

Between the lines: CBD and psychedelic medicine are very different. Cannabis oil doesn't produce a high like smoking marijuana does. Psychedelic drugs do still have profound effects on the brain, which is why they're so tightly regulated and scarcely used.

  • If there's a constant here, though, it's a willingness to look at, as ATAI puts it, "formerly stigmatized medicines."
  • The opioid epidemic has opened up new approaches to pain therapy; treatment-resistant depression demanded something; the criminal justice system is reevaluating drugs, too; and regulators are willing to give these products a shot.

Go deeper: Ahead of 2020, Kamala Harris supports marijuana legalization

Go deeper

12 mins ago - World

China-Iran deal envisions massive investments from Beijing

Illustration: Aïda Amer/Axios

China and Iran have negotiated a deal that would see massive investments flow into Iran, oil flow out, and collaboration increase on defense and intelligence.

Why it matters: If the proposals become reality, Chinese cash, telecom infrastructure, railways and ports could offer new life to Iran’s sanctions-choked economy — or, critics fear, leave it inescapably beholden to Beijing.

Updated 50 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 7 p.m. ET: 13,048,249 — Total deaths: 571,685 — Total recoveries — 7,215,865Map.
  2. U.S.: Total confirmed cases as of 7 p.m. ET: 3,353,348— Total deaths: 135,524 — Total recoveries: 1,031,856 — Total tested: 40,282,176Map.
  3. World: WHO head: There will be no return to the "old normal" for foreseeable future — Hong Kong Disneyland closing due to surge.
  4. States: Houston mayor calls for two-week shutdownCalifornia orders sweeping rollback of open businesses — Cuomo says New York will use formula to determine if reopening schools is safe.
  5. Education: Los Angeles schools' move to online learning could be a nationwide tipping point.

House Judiciary Committee releases transcript of Geoffrey Berman testimony

Geoffrey Berman. Photo: Alex Wong/Getty Images

The House Judiciary Committee on Monday released the transcript of its closed-door interview with Geoffrey Berman, the former top federal prosecutor in Manhattan who was forced out by Attorney General Bill Barr last month.

Why it matters: House Democrats have seized on Berman's testimony, in which he claimed the attorney general sought to "entice" him into resigning so that he could be replaced by SEC chairman Jay Clayton, to bolster allegations that the Justice Department has been politicized under Barr.